The General Pharmaceutical Council and the other eight regulators of health and care professionals have signed a joint statement setting out guidance on what is expected of all healthcare professionals in relation to avoiding, declaring and managing conflicts of interest across all healthcare settings.

The statement is intended to support each regulator’s professional standards, codes and guidance, which, the statement says, “should be the overriding consideration for professionals”.

Among the expectations outlined, the joint statement says healthcare professionals should “refuse all but the most trivial gifts, favours or hospitality” if accepting them could be seen as an attempt to gain preferential treatment or could go against their professional code of practice.

The statement also includes the following expectations of healthcare professionals:

  • Put the interests of people in their care before their own or those of any colleague or organisation
  • Consider where potential conflicts of interest may arise and be open about them
  • Be open about, and declare, any conflicts of interest they face
  • Reflect on their own learning and CPD needs regarding conflicts of interest
  • Ensure patients have access to visible information on any fees or charging policies for which they are responsible.

The regulators have published case studies to illustrate these principles.

Recommended

Go green again for Pharmacist Support!

Pharmacist Support wants pharmacy teams to once again ’Go Green’ for annual fundraising campaign next month

First graduates from Nottingham’s integrated course ready to practise

Students from Nottingham are the first to graduate as qualified pharmacists after completing an integrated MPharm degree

Popular

Health checks and diabetes prevention New Style

This module provides an update on both the NHS Health Check and NHS diabetes prevention programmes

CPD: Anxiety disorders in adults New Style

This module will help you understand the main types of anxiety disorder and their therapeutic management

Dovonex is switched from POM to P

Dovonex Psoriasis Ointment (calcipotriol 50mcg/g) has been reclassified as a P medicine, the MHRA has announced